Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib.

Shahriari, Saeedeh; Seifi, Sharareh; Khodakarim, Nastaran; Ramim, Tayeb; Dashtpeima, Alireza

Shahriari, Saeedeh; Seifi, Sharareh; Khodakarim, Nastaran; Ramim, Tayeb; Dashtpeima, Alireza.

Afiliação

Shahriari S; Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Seifi S; Department of Hematology & Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Khodakarim N; Department of Hematology & Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ramim T; Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Dashtpeima A; Department of Pediatrics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Med J Islam Repub Iran ; 36: 31, 2022.

Article em En | MEDLINE | ID: mdl-36128277

Palavras-chave

Epidermal Growth Factor Receptor; Erlotinib; Lung Cancer; Overall Survival; Progression-Free Survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google